Researchers from the Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen have discovered up to 100 potential cancer drug targets.

Using mass spectrometry-based proteomics to study mouse cells, researchers identified proteins that can be used for the personalised treatment of various cancer types and other diseases.

The study focused on protein communication and signalling and revealed the role of misregulation of signalling in enhanced tumour production.

Researchers used mass spectrometry proteomics to examine the proteins of cells that were treated with different growth hormones along with advanced data analysis. This led to the discovery of proteins that alter communication processes and inhibit cancer development.

“Now we are doing follow-up projects, looking specifically at leukaemia, where the cancer cells have mutations in these different receptors which can be regulated by Shp-2.”

By gaining better insights into the mechanisms and regulation of the signals, researchers uncovered target proteins. Initially, only few proteins that were regulated by a tyrosine phosphatase called Shp-2 were identified, but the use of mass spectrometry revealed several more targets.

These results could pave the way for the development of new tyrosine phosphatase-inhibiting drugs for cancer and other diseases such as Noonan syndrome.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Even though tyrosine kinase inhibitors are already in use, the new discoveries are important as most cancers can develop resistance to existing drugs.

Researchers are planning additional studies to determine the role and mechanisms of the identified proteins.

University of Copenhagen postdoc Tanveer Singh Batth said: “Now we are doing follow-up projects, looking specifically at leukaemia, where the cancer cells have mutations in these different receptors which can be regulated by Shp-2.”